ストックスクリーナーアプリを入手
258.31
0.27%
0.70
前日終値:
$257.61
開ける：
$251.03
24時間の取引高:
2.26M
Relative Volume:
2.12
時価総額：
$37.70B
収益：
$5.26B
当期純損益:
$1.44B
株価収益率:
26.44
EPS:
9.7713
ネットキャッシュフロー:
$1.76B
1週間 パフォーマンス:
+2.35%
1か月 パフォーマンス:
+6.27%
6か月 パフォーマンス:
-6.90%
1年 パフォーマンス:
+0.26%
1日の値動き範囲:
$245.21
$258.64
1週間の範囲:
$245.21
$261.00
52週間の値動き範囲:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
RMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
258.31 | 37.60B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
504.22 | 179.92B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
203.48 | 57.29B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.98 | 39.86B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.20 | 36.39B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
ResMed: Facing A Potentially Dream-Disrupting DoseStrong Sell - Seeking Alpha
ResMed outlines 62%–63% gross margin target for fiscal 2026 amid double-digit growth in key segments - MSN
ResMed Reaffirms 2025 Risk Profile: No Material Changes to Previously Disclosed Threats - TipRanks
Is Federal Agricultural Mortgage Corporation stock trending bullishGap Down & Technical Pattern Based Buy Signals - baoquankhu1.vn
ResMed Inc Earnings Call Shows Profitable Growth Momentum - TipRanks
RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth - Finviz
Breaking Down ResMed: 7 Analysts Share Their Views - Benzinga
ResMed’s Profitability Surge Driven by Operational Excellence - AD HOC NEWS
Explore ResMed Market Coverage and Healthcare Sector Context - Kalkine Media
Analysts Maintain Bull Case On ResMed Despite Competition Concerns - Benzinga
Resmed Q2: Mask sales surge as new products, resupply gain traction | - HME News
ResMed stock price target raised to $314 from $311 at RBC Capital By Investing.com - Investing.com South Africa
Wells Fargo & Company Forecasts Strong Price Appreciation for ResMed (NYSE:RMD) Stock - MarketBeat
Wells Fargo Analyst Raises ResMed (RMD) Price Target to $270 | R - GuruFocus
ResMed Inc. (NYSE:RMD) Declares Quarterly Dividend of $0.60 - MarketBeat
ResMed stock price target raised to $314 from $311 at RBC Capital - Investing.com Nigeria
KeyBanc raises ResMed stock price target to $302 on solid revenue beat - Investing.com
Wolfe Adjusts Price Target on ResMed to $230 From $225, Maintains Underperform Rating - marketscreener.com
KeyBanc Adjusts Price Target on ResMed to $302 From $299, Maintains Overweight Rating - marketscreener.com
Stifel Adjusts Price Target on ResMed to $265 From $260, Maintains Hold Rating - marketscreener.com
Resmed posts Street-beating Q2 results amid increased CPAP demand - MassDevice
Piper Sandler Adjusts Price Target on ResMed to $275 From $270, Maintains Neutral Rating - marketscreener.com
ResMed Inc. (NYSE:RMD) Q2 2026 Earnings Call Transcript - Insider Monkey
ResMed stock holds steady as Needham reiterates Hold rating By Investing.com - Investing.com Nigeria
ResMed stock holds steady as Needham reiterates Hold rating - Investing.com
Meridian Management Co. Buys Shares of 9,221 ResMed Inc. $RMD - MarketBeat
Pittenger & Anderson Inc. Has $26.81 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Medical device maker ResMed rises on Q2 profit beat - TradingView
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets - Morningstar
Tandem Investment Advisors Inc. Grows Stock Holdings in ResMed Inc. $RMD - MarketBeat
Why ResMed’s Hot Streak Has Investors Turning Cautious - TipRanks
RESMED INC SEC 10-Q Report - TradingView
ResMed (NYSE: RMD) grows revenue 11% and lifts margins in latest quarter - Stock Titan
ResMed Founder’s Horatio Alger Honor And What It Means For Investors - simplywall.st
ResMed (RMD) Maintains Quarterly Dividend of $0.60 Per Share - GuruFocus
AlphaQuest LLC Grows Stock Position in ResMed Inc. $RMD - MarketBeat
Horatio Alger Honor Puts ResMed Leadership And Growth Story In Focus - Yahoo Finance UK
ResMed Q2 Earnings Call Highlights - MarketBeat
ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations - GuruFocus
Ozempic-style drugs prove to be 'a tailwind' for Resmed - aapnews.aap.com.au
Stock of the day: ResMed - ig.com
ResMed shares slip after Q2 FY26 results release - AlphaStreet
ResMed Q2 FY26 presentation: Revenue up 9%, expanding margins amid digital health push - Investing.com Nigeria
ResMed’s Q2 margins keep climbing, while valuation sits below history - Market Index
Hot Stocks: ResMed, Etherstack, Chilwa Minerals, 4DMedical - Sharecafe
ResMed Shares Surge After Positive Results - Sharecafe
ResMed Q2 FY26 presentation: Revenue up 9%, expanding margins amid digital health push By Investing.com - Investing.com South Africa
Why 4DMedical, Appen, Nine Entertainment, and ResMed shares are storming higher today - The Motley Fool Australia
Stocks making the biggest moves at noon: Appen, ResMed, energy stocks and more - Market Index
ResMed (RMD.AX ASX) Q2 beats lift A$36.82 intraday 30 Jan 2026: watch margins - Meyka
Why is the ResMed share price jumping 7% today? - The Motley Fool Australia
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
1.07%
0.21%
大文字化:
|
ボリューム (24 時間):